BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15819867)

  • 1. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66).
    Wu JJ; Chen HM; Ko WC; Wu HM; Tsai SH; Yan JJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):169-75. PubMed ID: 17913434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
    Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
    Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
    Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
    Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
    Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase.
    Tsakris A; Ikonomidis A; Poulou A; Spanakis N; Pournaras S; Markou F
    J Antimicrob Chemother; 2007 Jul; 60(1):136-9. PubMed ID: 17491004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E
    Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002.
    Ho PL; Ho AY; Chow KH; Wong RC; Duan RS; Ho WL; Mak GC; Tsang KW; Yam WC; Yuen KY
    J Antimicrob Chemother; 2005 Jun; 55(6):840-5. PubMed ID: 15857942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
    Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
    J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
    [No Abstract]   [Full Text] [Related]  

  • 16. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
    Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
    Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Salmonella genomic island 1 (SGI1) among Proteus mirabilis clinical isolates in Dijon, France.
    Siebor E; Neuwirth C
    J Antimicrob Chemother; 2013 Aug; 68(8):1750-6. PubMed ID: 23580563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of plasmid-encoded extended spectrum beta-lactamases produced by a clinical strain of Proteus mirabilis.
    Mahrouki S; Ben-Achour N; Chouchani C; Ben-Moussa M; Belhadj O
    Pathol Biol (Paris); 2009 May; 57(3):e55-9. PubMed ID: 18456422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.